Dr. John Pullman, MD
Internal Medicine (Internal Medicine Physician)
300 W Mercury St
Butte, MT 59701
Who else practices at this address →
Silver Bow County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Rochester School of Medicine and Dentistry (1977)
- Years since graduation
- 49
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 370
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1977Medical school: University of Rochester School of Medicine and Dentistry
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
MT license 4792 -
Critical Care Medicine (Internal Medicine) Physician
MT license 4792 -
Infectious Disease Physician
MT license 4792
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St James Hospital Butte, MT
- Barrett Hospital & Healthcare Dillon, MT
- Community Hospital of Anaconda Anaconda, MT
Medical groups
- Cogent Healthcare of Montana P C (79 clinicians)
- Mercury Street Medical Group PLLC (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 370
- Services billed
- 8,292
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Insertion of needle into vein for collection of blood sample | 835 | 301 |
| Blood test, comprehensive group of blood chemicals | 714 | 297 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 710 | 294 |
| Established patient office or other outpatient visit, 30-39 minutes | 584 | 272 |
| Blood test, thyroid stimulating hormone (tsh) | 466 | 234 |
| Hemoglobin a1c level | 364 | 182 |
| Manual urinalysis test with examination using microscope, automated | 309 | 163 |
| Measurement c-reactive protein for detection of infection or inflammation | 263 | 131 |
| Blood test, lipids (cholesterol and triglycerides) | 246 | 182 |
| Creatinine level to test for kidney function or muscle injury | 236 | 126 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 61 payments worth $2,135 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,221 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $149 |
| Amgen Inc. | $146 |
| AbbVie Inc. | $75.41 |
| Novo Nordisk Inc | $55.07 |
| Novartis Pharmaceuticals Corporation | $52.81 |
| Exact Sciences Corporation | $50.79 |
| Insulet Corporation | $49.88 |
| Food and Beverage | $1,482 |
|---|---|
| Travel and Lodging | $653 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 15, 2025 | Travel and Lodging travel to DFW Airport, TX · in-kind | $251 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 10, 2025 | Travel and Lodging travel to DFW Airport, TX · in-kind | $204 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 10, 2025 | Travel and Lodging travel to DFW Airport, TX · in-kind | $199 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 10 companies. The companies reported $500,899 in research payments for these studies, mostly to the institutions running them.
- A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06299098 - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity
Hoffmann-la Roche Limited - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - Study name not reported
Novo Nordisk As
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.